Decreased Survival With Mastectomy Vis-à-Vis Breast-Conserving Surgery in Stage II and III Breast Cancers: A Comparative Treatment Effectiveness Study abstract Purpose The primary purpose of hospital-based cancer registries is assessing patient care. Clinical stage-based survival and treatment-based survival are some of the key parameters for such assessment. Because of the challenges in obtaining follow-up parameters, a separate study on patterns of care and survival was undertaken by the Indian National Cancer Registry Program. The results for cancer of the female breast are presented here.
INTRODUCTION
Worldwide, breast cancer is the most common cancer among women, composing 25% of all female cancers. 1 The annual estimated incidence of new breast cancers in women in India is approximately 100,000. Breast cancer has shown a statistically significant increase in incidence rates over time in the Indian Population-Based Cancer Registries. 2 Information on patterns of breast cancer care and survival is essential in assessing cancer treatment services, and a hospital-based cancer registry is central to this effort. 3 There are several challenges in obtaining proper and accurate data on clinical stage-based survival in the setting of a developing country. These include treatment compliance and post-treatment followup, including relevant information on recurrence and/or complications of disease. 4 The main aim of this study was to obtain clinical stage-specific treatment and survival information for breast cancer in India.
collaborating institutions with the Internet as the medium of transmission to a central repository. An earlier version of this method, which constituted the basic design and framework for obtaining information, has been described previously. 12 
PATIENTS AND METHODS
Thirteen institutions participated in the study (Data Supplement). A standardized patient information form (PIF; Data Supplement) developed by oncologists with specific expertise in breast cancer was hosted on a Web site (www.hbccrindia.org).
Printed forms with an instruction manual were supplied to participants. Trained staff completed the form through a combination of patient-attendant interviews; scrutiny of medical records, other relevant documents, and registers; and discussions with concerned clinicians. Collaborating centers were given individual login identifications and passwords with instructions for online data entry to electronically transmit the data to a central repository, the National Centre for Disease Informatics and Research (NCDIR Analysis was carried out separately for stages I, II, and III. Patients with stage IV disease (which is exclusively a metastatic disease) and patients whose stage was unknown were excluded from this study.
Surgical Treatment
Patients who had undergone lumpectomy with or without axillary lymph node clearance were defined as having received BCS, whereas patients who had simple MS (with or without axillary lymph node clearance) or radical MS were classified as having had MS.
Radiotherapy
Patients who had received radiotherapy (RT) to the chest wall (> 45 Gy) with or without an additional boost with radical intent were considered as having received optimal RT, and those who received less than this dose were considered as have received suboptimal RT. Patients treated with palliative intent RT or RT given only to the axilla and/or supraclavicular nodes were excluded. Few patients (1.6%) received RT through such techniques as intensity-modulated RT or image-guided RT, so these factors were disregarded.
Chemotherapy
Chemotherapy was considered as given if the patient received it as neoadjuvant, concurrent, or adjuvant chemotherapy. Standard prescribed protocols in use of specific chemotherapy drugs were followed. Anthracyclines with and without taxanes and/or other drug combinations were analyzed separately. Because few patients (n = 23) were given trastuzumab, no separate analysis was done on this.
Hormone Therapy
Patients who received neoadjuvant or adjuvant intervention with surgical oophorectomy, RT-ovarian ablation, medical tamoxifen, or aromatase inhibitors were considered as having received hormone therapy (HT).
Receptor Status
Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status was determined in all patients and was classified as triple negative, triple positive, ER and PR positive and HER2 negative, and other combinations.
Software Programs and Quality Checks
In-house Internet-based software programs (www. hbccrindia.org; www.ncdirindia.org) were modeled for data capture, checked for completeness and consistency, tracked patient follow-up, updated treatment information, and recorded follow-up details. Checks done on data varied from date checks to verifying discrepancies in clinical information (Data Supplement). Lists of patients with improbable data were sent back to concerned centers for rectification. Further, a center-wise random sample of 10% of patients was listed, and centers were asked to reabstract the medical records for certain essential parameters; the matching results were found to be 95% accurate.
Statistical Analysis
The Kaplan-Meier method 14 and Cox proportional hazards regression 15 in the SPSS package (version 21; SPSS, Chicago, IL) were used to calculate 5-year cumulative survival (FCS) rate and fatality risk (with statistical significance), respectively.
Multivariate analysis was performed using Cox proportional hazard regression analysis.
RESULTS
The Data Supplement provides patient, diagnostic, and treatment characteristics for the 9,903 patients with breast cancer in whom patterns of care were examined and for the 7,609 patients in whom survival analysis was also done. Overall, the FCS rate in 7,609 patients was 73.8%, varying from 93.3% in patients with stage I disease to 24.5% in patients with stage IV disease. Analysis was done separately for the BCS and MS groups to examine the possible reasons for the relatively poorer survival in patients with MS (Tables 2 and 3 ). For patients with BCS, inclusion of RT, which constitutes breast-conservation therapy (BCT), significantly increased the survival compared with patients who had not received RT. For patients who had MS, addition of both chemotherapy and HT significantly increased survival, whereas there was no improvement in survival with addition of RT ( Table 3 ).
The overall findings were similar when analysis was done separately for stage IIA and IIB disease. As in patients with stage II disease, the overall findings were similar when analysis was done separately for stage IIIA and stage IIIB. Also as in patient with stage II disease, node-positive MS patients (N1-3) had a significantly lower survival when optimal RT and/or HT were not administered compared with MS patients who had received these therapies. Table 5 compares the survival rates in this study with those in other key reports. The survival benefit of BCS, especially in stage II and III breast cancer, seems to be greater in this study when compared 5, 16, 18, 19 Other aspects that have been compared are initial tumor size, patterns of recurrence, and time to locoregional recurrence or distant metastases. 6, 20 These studies have shown that there is no difference in survival between the two types of surgery. A national registry-based stage-by-stage comparison has also shown equal survival for BCS and MS. 21 A meta-analysis by Yang et al 22 showed that OS was not statistically significant between patients who underwent MS and BCT.
However, recent publications from Canada 23 and results from the SEER database 8 show better survival of patients with BCT compared with MS. A report presented at the San Antonio Breast Cancer Symposium in December 2015 on an observational study of 37,000 women showed a better survival with BCT than with MS (76.8% v 59.7%, respectively). 24 There have been single-institution reports from India comparing survival in patients receiving BCS and those receiving MS. 10, 11 To our knowledge, this is the first multi-institutional study in India to provide insight into the extent of practice of BCS vis-à-vis MS and the survival differences between these two treatments. It is not a randomized clinical trial, but it nonetheless gives an accurate picture of the patterns of care and survival in the natural arena of selection of patients with cancer for a specific type cancer 25 The strengths, opportunities, and limitations of this study, which is identical to the one on cervical cancer, have been outlined previously. 26 The differences observed in survival are a result of a combination of treatment modality and selection criteria of patients. The latter are unknown and have not been taken into account. However, there is no selection bias because all patients who received cancer-directed treatment in their respective institutions have been accounted for, and exclusion criteria are based on scientific logic. 26 Other limitations specific to this study are that in a high proportion of patients (pattern of care, 33.4%; pattern of survival, 28.6%) information on receptor status was not available and a substantial number of patients with stage I (10 patients), stage II (130 patients), and stage III disease (336 patients) did not receive any surgical treatment. Because there was no information as to why surgery was not done in these patients, we were unable to provide the clinical or other rationale for this result.
This study is a foremost example of cancer registration (through a national program of cancer registries covering several cancer centers and medical institutions) evaluating clinical parameters and providing critical findings that could have an impact on patient care. A network of cancer hospitals linked to a central coordinating center (NCDIR) with a system to accrue good clinical data through modern electronic information technology is in place.
The differences in survival that were observed between MS and BCS are significant and substantial. The difference was 8.2% for patients with stage II disease and as high as 18.1% for patients with stage III disease, with the results being the same even when separately analyzed according to stages IIIA and IIIB. The results presented here are those of pooled data from several institutions. The data of individual centers were separately examined to ascertain whether there were any variations among institutions in the survival or the extent of survival difference between BCS and MS. A comparable survival pattern and difference were observed in all institutions. Age and rate of recurrence or complications were also similar between the two groups. The variation in other treatments impacting survival between patients who had received BCS and MS shows that for stage II disease, RT plays a major role for BCS but not for MS, although relatively more MS patients received less RT and suboptimal RT. The roles of chemotherapy and HT seem less important than RT for BCS, whereas these treatments (chemotherapy and HT) are more important for improved survival in the MS group. The need for greater systemic therapy in patients with MS in contrast to those who had BCS is difficult to explain. One could hypothesize that removal of the breast as a result of MS entails loss of patient immunity that requires additional systemic therapy.
A similar picture was observed in stage III disease where patients who had MS did better when they received a combination of RT, chemotherapy, and HT, whereas in patients who had BCS, RT alone was sufficient to have equivalent survival. The proportions of patients with stage II and III disease in the pattern-of-care group (all 13 institutions) who underwent BCS were 29.5% and 12.8%, respectively (Data Supplement).
In conclucion, the findings justify further investigation of the possible reasons for decreased survival in patients with MS. The underlying cause of death, including the events that lead to it, whether a result of early or late complications of treatment, needs to be studied. A wellsubstantiated analysis of this parameter would require availability of accurate and complete information on these characteristics in a majority of patients, which was not available in the current study. Because obtaining such data is hugely challenging in the routine Indian setting, a randomized study on the cause of death in patients with breast cancer could provide insights. Such studies could take into account additional and further details of points that were not gathered in this study, including information on individual caregivers, socioeconomic status of patients, and additional details on investigations done for staging. There seems to be a need to promote awareness about the distinct advantages of BCS in the context of developing countries, and further studies are required to examine the biologic or scientific rationale of the requirement of systemic therapy in patients with MS but not in those with BCS.
